National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 13: Insulin-Dependent Diabetes Mellitus

« Previous: Appendix 12: Influenza A and B
Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 13
Insulin-Dependent Diabetes Mellitus

Insulin-dependent diabetes mellitus (IDDM) is becoming one of the most studied autoimmune diseases. The pathogenesis of IDDM involves a sequence of events ultimately leading to the destruction of beta cells of the pancreas which normally function as the insulin-producing cells. First, there must be a genetic susceptibility to the disease. Next, an environmental event, possibly a virus, initiates the disease process. Once the disease has been triggered, an inflammatory response called “insulitis” begins in the pancreas. Insulitis is an inflammatory infiltrate composed mainly of T lymphocytes which invade the cells of the pancreas. The fourth step is a transformation in the surface of the beta cells causing the activation of the autoimmune response. This response occurs because the beta cell is no longer recognized as “self” but is targeted as a “nonself” foreign cell. As a result, the beta cells are destroyed, which leads to the appearance of diabetes mellitus.

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are approximately 30,000 new cases of insulin-dependent diabetes mellitus (IDDM) each year in the United States. It was assumed that the incidence varies slightly with age, but that the highest incidence occurs in people between 5 and 34 years of age.

Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that there are two phases of health states associated with IDDM. During the first 20 years, it is assumed that on average, patients experience minor discomforts and only occasional, serious health incidents. This phase was assumed to be associated with a health utility index (HUI) of .97. During the second phase, which lasts for the duration of the person’s life, there are many possible complications with varying impacts on a HUI. On average, it was assumed that this phase was associated with an HUI of .79. It was assumed that patients with IDDM, on average, experience a decrease in life expectancy of approximately 12 years. This was calculated as one-third reduction of life expectancy at the time of onset of the disease.

COST INCURRED BY DISEASE

Table A13–1 summarizes the health care costs incurred by IDDM. For the purposes of the calculations in this report, it was assumed that 70% of patients receive conventional treatment for IDDM and 30% receive intensive treatment. It is assumed that there are costs associated with the diagnostic and very early phase of treatment, with the disease management during the 20-year period that was assumed to be free of chronic, serious sequelae, and with the disease management during the second phase, as well as costs associated with serious complications.

It will be assumed that a therapeutic vaccine strategy will only reduce costs associated with long-term management of disease and treatment of complications. The initial diagnostic phase will not be eliminated. Therefore, only the preventable costs will be described in detail. Costs incurred during the first 20 years of disease management include outpatient visits to specialists (endocrinologists and ophthalmologists, for example) and associated diagnostics, occasional visits to diabetes case managers/educators, and treatment for severe hypoglycemia in some patients. Self-care supplies are assumed to include insulin, syringes, and blood glucose monitoring supplies. It is assumed that patients in intensive treatment incur higher costs due to more frequent physician visits, diagnostics, and supplies.

Costs incurred due to serious complications associated with IDDM are also approximated for the calculations in the report. For example, it was assumed that 60% of people with IDDM will require treatment for retinopathy, renal evaluation and angiotensin-converting enzyme-inhibitor medication, and neurologic evaluation. It is assumed that 20% incur additional costs associated with blindness and end-stage renal disease. It was also assumed that a small percentage of patients will require amputation and associated costs.

The committee assumed that it will take 15 years until licensure of a therapeutic IDDM vaccine and that $360 million needs to be invested. Table 4–1

Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

summarizes vaccine development assumptions for all vaccines considered in this report.

For the purposes of the calculations in this report, it is assumed that the costs associated with diagnostic phase would be incurred even with a treatment vaccine strategy. Therefore, only the costs of the treatment phase will be assumed to be averted with a vaccine strategy.

VACCINE DEVELOPMENT

The committee assumed that it will take 15 years until licensure of a therapeutic IDDM vaccine and that $360 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is all newly diagnosed cases of IDDM. It was assumed that 90% of the target population would utilize the vaccine.

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $500 per dose and that administration costs would be $10 per dose. Default assumptions for therapeutic vaccines of a 3-dose series and 40% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for IDDM were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 170,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 38,000.

Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A13–1 Health Care Costs Associated with IDDM

 

% of Cases

Duration (years)

% with Care

Cost per Unit

Units per Case

Form of Treatment

First 20 years

100%

 

CONVENTIONAL THERAPY—70%

Treatment phase

Yearly

Hypoglycemia

20.00

20%

$500

1.0

Treatment of severe hypoglycemia

 

20.00

35%

$100

1.0

Treatment modification

Physician visits and diagnostics

20.00

35%

$150

4.0

Quarterly visit plus diagnostic

 

 

20.00

35%

$150

2.0

Semiannual visit plus diagnostic

20.00

35%

$150

1.0

Specialist visit plus diagnostic

20.00

35%

$50

1.0

Case management, counseling

Self-management

20.00

70%

$15

18.0

Insulin

 

20.00

70%

$100

12.0

Other supplies

INTENSIVE THERAPY—30%

Treatment phase

Yearly

Hypoglycemia

20.00

15%

$500

1.0

Treatment of severe hypoglycemia

Physician visits and diagnostics

20.00

30%

$150

1.0

Quarterly visit (endocrinologist)

 

 

20.00

30%

$500

1.0

Annual visit (e.g., ophthalmologist)

20.00

30%

$50

2.0

Case management, counseling

Self-management

20.00

30%

$16

24.0

Insulin

 

20.00

30%

$200

12.0

Other supplies

Remainder of life

100%

 

Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

CONVENTIONAL THERAPY

Hypoglycemia

15.00

15%

$500

1.0

Treatment of severe hypoglycemia

 

15.00

5%

$220

1.0

Treatment modification

Physician visits and diagnostics

15.00

70%

$80

2.0

Quarterly visit

 

15.00

70%

$100

1.0

Semiannual visit

15.00

70%

$250

1.0

Annual visit

15.00

70%

$50

1.0

Case management, counseling

Self-management

15.00

70%

$16

24.0

Insulin

INTENSIVE THERAPY

Hypoglycemia

15.00

30%

$500

1.0

Treatment of severe hypoglycemia

Physician visits and diagnostics

15.00

30%

$70

8.0

Monthly visit

 

15.00

30%

$120

2.0

Quarterly visit

15.00

30%

$120

1.0

Semiannual visit

15.00

30%

$280

1.0

Annual visit

15.00

30%

$50

1.0

Case management, counseling

Self-management

15.00

30%

$16

24.0

Insulin

 

15.00

30%

$2,000

1.0

Other supplies

COMPLICATIONS (conventional and intensive treatment)

Retinopathy

Episodic

 

60%

$950

1.0

Photocoagulation

Chronic treatment

7.00

20%

$1,900

1

Blindness

Nephropathy

Episodic

 

60%

$1,100

1.0

Renal evaluation

Chronic treatment

7.00

20%

$46,000

1

End-stage renal disease treatment (per year)

Neuropathy

Episodic

 

60%

$125

1.0

Neurologic evaluation

 

5%

$31,225

1.0

Lower extremity amputation

Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

If a vaccine program for IDDM were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $2.5 billion. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $550 million.

If a vaccine program for IDDM were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $45 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $25 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for an IDDM vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is -$14,500. A negative value represents a saving in costs in addition to a saving in QALYs. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is -$13,500.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

DERI Mortality Study Group. International Analysis of Insulin-Dependent Diabetes Mellitus Mortality: A Preventable Mortality Perspective. American Journal of Epidemiology 1995; 142:612–618.


Gorham ED, Garland FC, Barrett-Connor E, et al. Incidence of Insulin-Dependent Diabetes Mellitus in Young Adults: Experience of 1,587,630 US Navy Enlisted Personnel. American Journal of Epidemiology 1993; 138:984–987.


Metcalfe MA, Baum JD. Incidence of Insulin-Dependent Diabetes in Children Aged Under 15 years in the British Isles During 1988. BMJ 1991; 302:443–447.

Mølbak AG, Christau B, Marner B, et al. Incidence of Insulin-Dependent Diabetes Mellitus in Age Groups Over 30 years in Denmark. Diabetic Medicine 1994; 11:650–655.


National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Statistics [WWW document]. URL http://www.niddk.nih.gov/index.htm (accessed September 23, 1996).


Schoenle EJ, Molinari L, Bagot M, et al. Epidemiology of IDDM in Switzerland. Diabetes Care 1994; 17:955–960.

Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 233
Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 234
Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 235
Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 236
Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 237
Suggested Citation:"Appendix 13: Insulin-Dependent Diabetes Mellitus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 238
Next: Appendix 14: Melanoma »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!